Clinical Trials Logo

Clinical Trial Summary

This study will assess the safety and efficacy of ARQ-154 foam vs vehicle applied once daily for 8 weeks by subjects with scalp and body psoriasis.


Clinical Trial Description

This is a parallel group, double blind, vehicle-controlled study in which ARQ-154 foam or vehicle foam is applied once daily for 8 weeks to subjects with scalp and body psoriasis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05028582
Study type Interventional
Source Arcutis Biotherapeutics, Inc.
Contact Arcutis Study Inquiry
Phone 805.418.5006 Ext. 5
Email [email protected]
Status Recruiting
Phase Phase 3
Start date August 24, 2021
Completion date December 2022

See also
  Status Clinical Trial Phase
Completed NCT01195831 - Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis Phase 3
Completed NCT00400725 - Maintenance Effect of Clobex Shampoo on Subjects With Moderate to Severe Scalp Psoriasis Phase 3
Completed NCT03880357 - To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis Phase 1
Completed NCT03331523 - To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis Phase 3
Completed NCT04801433 - Evaluate the Efficacy and Safety of Boroda Supramolecular Active Zinc in the Treatment of Scalp Psoriasis N/A
Completed NCT01120223 - Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis Phase 2
Active, not recruiting NCT03897088 - Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasi Phase 3
Completed NCT02932462 - Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis Phase 3
Completed NCT02933866 - Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis Phase 3
Completed NCT02933502 - Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product Phase 2
Completed NCT01052467 - Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel) N/A
Completed NCT04243486 - A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis Phase 2
Recruiting NCT02749656 - Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis Phase 3
Completed NCT02078297 - IL-17 Role in Variants of Psoriasis N/A
Completed NCT00438399 - Subject Preference for Scalp Psoriasis Treatment Phase 3
Completed NCT01914627 - Parallel Group Trial to Evaluate the Efficacy and Safety of Loion® Compared to 10% Salicylic Acid in Patients With Chronic Psoriasis Capitis Phase 2
Not yet recruiting NCT01558310 - A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis Phase 4
Completed NCT01083758 - Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis Phase 2
Completed NCT00881868 - Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp Phase 4
Completed NCT03122353 - BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis Phase 1